{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:52:10Z","timestamp":1753890730294,"version":"3.41.2"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2023.1277101","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T21:34:34Z","timestamp":1694122474000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial: Secreted proteins as novel biomarkers and therapeutic targets in NAFLD"],"prefix":"10.3389","volume":"14","author":[{"given":"Xuelian","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.028","article-title":"NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned","volume":"78","author":"Rasmussen","year":"2023","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00639-3","article-title":"Immune cell-mediated features of non-alcoholic steatohepatitis","volume":"22","author":"Huby","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7326\/AITC201811060","article-title":"Nonalcoholic fatty liver disease","volume":"169","author":"Wang","year":"2018","journal-title":"Ann Intern Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00502-9","article-title":"Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests","volume":"18","author":"Masoodi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"volume-title":"BEST (Biomarkers, endpointS, and other tools) resource","year":"2016","key":"B8"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1039\/C4CS00370E","article-title":"Cancer biomarker detection: recent achievements and challenges","volume":"44","author":"Wu","year":"2015","journal-title":"Chem Soc Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.56","article-title":"Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance","volume":"13","author":"Meex","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1210\/er.2019-00034","article-title":"The liver as an endocrine organ-linking NAFLD and insulin resistance","volume":"40","author":"Watt","year":"2019","journal-title":"Endocr Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.022","article-title":"Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism","volume":"64","author":"Wan","year":"2016","journal-title":"J Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.jhep.2015.01.019","article-title":"Xanthine oxidase in non-alcoholic fatty liver disease and hyPeruricemia: One stone hits two birds","volume":"62","author":"Xu","year":"2015","journal-title":"J Hepatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jhep.2020.04.001","article-title":"Lytic cell death in metabolic liver disease","volume":"73","author":"Gautheron","year":"2020","journal-title":"J Hepatol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1277101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T21:34:37Z","timestamp":1694122477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1277101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":14,"alternative-id":["10.3389\/fendo.2023.1277101"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1277101","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"article-number":"1277101"}}